Latest News
About Tonix Pharmaceuticals
Tonix is a biotechnology company where scientific breakthroughs begin with respecting the patients’ lived experiences. Our pipeline responds to the call for solutions to complex, chronic and sometimes invisible conditions with scientific rigor, integrity, and purpose. We are dedicated to developing therapies for conditions that defy easy answers, including nociplastic pain, immunology / immuno-oncology, and infectious diseases. We aim to develop impactful treatments that make patients feel seen and heard, reducing the limitations these conditions impose, enabling people to expect more, and be energized by possibility.
At Tonix, we listen, we develop, we deliver – so that patients feel seen, heard, and empowered to live fully again.
Therapeutic Areas
Central Nervous System
Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.
Immunology
We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*
Infectious Disease
Tonix’s infectious disease portfolio targets pathogenic infections, including monkeypox and smallpox for biodefense. Through its live virus vaccine platform and in-house capabilities, Tonix strives to be prepared for future pandemics.
Rare Diseases
Tonix is committed to improving patient care, including for those suffering from rare diseases, often for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.
Key Clinical & Preclinical Programs
Using our integrated clinical development engine, we advance innovative programs into the clinic while maximizing asset potential.
Preclinical
Phase I
Phase II
Phase III
TNX-102 SL Acute Stress Disorder
Topline data expected 2nd half 2026. Phase 2 enrolling.
Phase 2
TNX-1500 Organ Transplant Rejection / Autoimmune Disorders
Phase I — Clinical phase complete
Phase 2
TNX-2900 Prader-Willi Syndrome
Phase II Ready — FDA Orphan Drug and Rare Pediatric Disease Designation
Phase 2 Ready
TNX-1700 Gastric and Colorectal Cancer
Preclinical
Preclinical
TNX-801 Prevention of Mpox or Smallpox
Preclinical
Preclinical
TNX-4200 CD45
Preclinical
Preclinical